Canaccord Genuity Welcomes Ed Nash, Managing Director, Equity Research7th October 2019
Canaccord Genuity is pleased to welcome Edward Nash, Managing Director, Equity Research to our New York office. With nearly 20 years of experience in the biotechnology sector, Edward joins Canaccord Genuity’s team to focus on companies developing innovative antibiotics and treatments for liver disease. With this addition, Edward rounds out Canaccord Genuity’s market-leading biotechnology team of five senior analysts who leverage combined research experience of over seventy years to analyze all facets of the sector including oncology, neurology, rare diseases, metabolic disorders and gene therapy.
Edward received his M.B.A from the University of Miami, M.P.H from the University of Alabama at Birmingham, and his B.A. from Spring Hill College. Previously, Edward has held senior research positions at several firms including Cowen and SunTrust Robinson Humphrey.
Edward joining Canaccord Genuity underscores the firm’s commitment to Life Sciences and Healthcare, which in addition to the biotechnology sector, includes in-depth coverage of medical technology, diagnostics, healthcare services, and healthcare IT. We look forward to building on the success and accomplishments we have enjoyed in these segments.
How can we help?
If you would like to find out more about Canaccord Genuity or any of our services, please get in touch.